Sequenom (NASDAQ: SQNM) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $27.8 million versus the consensus estimate of $27.8 million.

Fourth quarter total accessions of 42,200, up from 41,000 in Q3 2015
Fourth quarter noninvasive prenatal test (NIPT) accessions of 37,300, up from 35,500 in Q3 2015

For earnings history and earnings-related data on Sequenom (SQNM) click here.